Speaker Name: Dr. John Buse, Director, UNC Diabetes Care Center, Chicago, USA.

Access the session to:

• Understand the rationale for the SOUL cardiovascular outcomes trial in high-risk T2DM.
• Review how T2DM care now extends beyond HbA1c to ASCVD, HF, CKD, stroke, PAD, and obesity risk reduction.
• Learn how oral semaglutide was evaluated in a randomized, placebo-controlled trial and why correct administration is important for drug exposure.
• Interpret key endpoints, including 3-point MACE, renal outcomes, CV death, limb events, and HF outcomes.
• Gain insight into how SOUL complements evidence from FLOW, SELECT, and STRIDE trials.